Pharma Mar, S.A. (PHMMF)
OTCMKTS · Delayed Price · Currency is USD
88.72
0.00 (0.00%)
Feb 11, 2026, 4:00 PM EST
Pharma Mar Revenue
Pharma Mar had revenue of 35.66M EUR in the quarter ending September 30, 2025, a decrease of -21.88%. This brings the company's revenue in the last twelve months to 179.28M, up 7.35% year-over-year. In the year 2024, Pharma Mar had annual revenue of 174.86M with 10.56% growth.
Revenue (ttm)
179.28M EUR
Revenue Growth
+7.35%
P/S Ratio
7.34
Revenue / Employee
358.55K EUR
Employees
500
Market Cap
1.54B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 174.86M | 16.70M | 10.56% |
| Dec 31, 2023 | 158.15M | -38.19M | -19.45% |
| Dec 31, 2022 | 196.34M | -33.49M | -14.57% |
| Dec 31, 2021 | 229.83M | -40.13M | -14.87% |
| Dec 31, 2020 | 269.96M | 184.14M | 214.57% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Arch Biopartners | 198.11K |
Pharma Mar News
- 1 year ago - Pharma Mar SA (PHMMF) Q4 2024 Earnings Call Highlights: Record Profits and Strategic Advances - GuruFocus
- 3 years ago - Pharma Mar, S.A. (PHMMF) Q4 2022 Earnings Call Transcript - Seeking Alpha
- 4 years ago - Pharma Mar, S.A. (PHMMF) Management on Q4 2021 Results - Earnings Call Transcript - Seeking Alpha